These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 32591311)

  • 1. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study.
    Luciani A; Marra A; Toschi L; Cortinovis D; Fava S; Filipazzi V; Tuzi A; Cerea G; Rossi S; Perfetti V; Rossi A; Giannetta L; Sala L; Finocchiaro G; Pizzutilo EG; Carelli S; Agustoni F; Cergnul M; Zonato S; Siena S; Bidoli P; Ferrari D
    Clin Lung Cancer; 2020 Nov; 21(6):e567-e571. PubMed ID: 32591311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
    Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.
    Galli G; De Toma A; Pagani F; Randon G; Trevisan B; Prelaj A; Ferrara R; Proto C; Signorelli D; Ganzinelli M; Zilembo N; de Braud F; Garassino MC; Lo Russo G
    Lung Cancer; 2019 Nov; 137():38-42. PubMed ID: 31526910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.
    Aguilar EJ; Ricciuti B; Gainor JF; Kehl KL; Kravets S; Dahlberg S; Nishino M; Sholl LM; Adeni A; Subegdjo S; Khosrowjerdi S; Peterson RM; Digumarthy S; Liu C; Sauter J; Rizvi H; Arbour KC; Carter BW; Heymach JV; Altan M; Hellmann MD; Awad MM
    Ann Oncol; 2019 Oct; 30(10):1653-1659. PubMed ID: 31435660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
    Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
    J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
    Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
    J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma.
    Lee J; Choi Y; Jung HA; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
    Eur J Cancer; 2020 Jun; 132():150-158. PubMed ID: 32371248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.
    Liang H; Xu Y; Chen M; Zhong W; Wang M; Zhao J
    Thorac Cancer; 2020 Apr; 11(4):1068-1075. PubMed ID: 32129934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival.
    Velcheti V; Chandwani S; Chen X; Piperdi B; Burke T
    Clin Lung Cancer; 2020 Sep; 21(5):e445-e455. PubMed ID: 32376116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression.
    Tambo Y; Sone T; Shibata K; Nishi K; Shirasaki H; Yoneda T; Araya T; Kase K; Nishikawa S; Kimura H; Kasahara K
    Clin Lung Cancer; 2020 Sep; 21(5):e366-e379. PubMed ID: 32199806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
    Morita R; Okishio K; Shimizu J; Saito H; Sakai H; Kim YH; Hataji O; Yomota M; Nishio M; Aoe K; Kanai O; Kumagai T; Kibata K; Tsukamoto H; Oizumi S; Fujimoto D; Tanaka H; Mizuno K; Masuda T; Kozuki T; Haku T; Suzuki H; Okamoto I; Hoshiyama H; Ueda J; Ohe Y
    Lung Cancer; 2020 Feb; 140():8-18. PubMed ID: 31838169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing.
    Kim HS; Cha H; Kim J; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Eur J Cancer; 2019 Oct; 120():65-74. PubMed ID: 31493723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer.
    Sakai T; Udagawa H; Matsumoto S; Yoh K; Nosaki K; Ikeda T; Zenke Y; Kirita K; Niho S; Akimoto T; Goto K; Ishii G
    J Cancer Res Clin Oncol; 2021 Apr; 147(4):1227-1237. PubMed ID: 32997195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer.
    Park S; Choi YD; Kim J; Kho BG; Park CK; Oh IJ; Kim YC
    Thorac Cancer; 2020 Feb; 11(2):408-414. PubMed ID: 31841269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer.
    Lichtenstein MRL; Nipp RD; Muzikansky A; Goodwin K; Anderson D; Newcomb RA; Gainor JF
    J Thorac Oncol; 2019 Mar; 14(3):547-552. PubMed ID: 30476576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.
    Besse B; Garrido P; Cortot AB; Johnson M; Murakami H; Gazzah A; Gil M; Bennouna J
    Lung Cancer; 2020 Apr; 142():63-69. PubMed ID: 32114283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.
    Marur S; Singh H; Mishra-Kalyani P; Larkins E; Keegan P; Sridhara R; Blumenthal GM; Pazdur R
    Semin Oncol; 2018 Aug; 45(4):220-225. PubMed ID: 30391014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.